Clinical Study on Qingre Dingjing Powder in the Treatment of Acute Respiratory Infections with High Fever in Children

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2025002057

Enrollment

Unknown

Registered

2025-10-28

Start date

2025-12-01

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Infection with High Fever

Interventions

Experimental Group:Qingre Dingjing Powder + Ibuprofen Suspension + Symptomatic Treatment

Control Group:Ibuprofen Suspension + Symptomatic Treatment

Eligibility

Sex/Gender

All

Age

1 Years to 6 Years

Inclusion criteria

Inclusion criteria: (1) Age 1-6 years (inclusive), no gender restrictions; (2) Meet clinical diagnostic criteria for acute respiratory infection; (3) Meet diagnostic criteria for high fever (axillary temperature =39.0?); (4) Legal guardian consents to participate and signs informed consent.

Exclusion criteria

Exclusion criteria: (1) Respiratory infections caused by primary diseases: primary immunodeficiency, AIDS, congenital respiratory malformations, congenital heart disease. (2) Respiratory infections caused by other primary diseases: pneumonia, lung abscess, tuberculosis, bronchiectasis, asthma, bronchial foreign body, hyperthyroidism, rheumatic fever. (3) Children with diarrhea, acute gastroenteritis or other digestive system diseases. (4) Diabetes, rickets, calcium/phosphorus metabolism disorders, or severe malnutrition. (5) Severe primary diseases of heart, liver, kidney or hematopoietic system; abnormal liver/kidney function (ALT/AST =1.5×ULN, SCr >ULN). (6) Glucose-6-phosphate dehydrogenase deficiency (favism). (7) Severe allergies, suspected drug component allergy, or contraindications. (8) Participation in other drug trials within 1 month. (9) Other conditions deemed unsuitable by investigators.

Design outcomes

Primary

Measure	Time frame
Fever Onset Time, Defervescence Time, Complete Fever Resolution Time;	—

Secondary

Measure	Time frame
Body Temperature Monitoring;Blood Routine and C-Reactive Protein;Disappearance Time of Main Accompanying Symptoms;Wong-Baker FACES Pain Rating Scale;Clinical Efficacy;Incidence of Febrile Convulsions;Ibuprofen Usage;	—

Countries

China

Contacts

Public ContactXiang Ma

Jinan Children's Hospital

maxiang0176@163.com15965626966

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026